Author + information
- Abbas Ali Qayyum,
- Anders Mathiasen,
- Naja Mygind,
- Tobias Kuhl,
- Erik Joergensen,
- Steffen Helqvist,
- Jens Jørgen Elberg,
- Klaus Kofoed,
- Niels Vejlstrup,
- Anne Fischer-Nielsen,
- Mandana Haack-Sørensen,
- Annette Ekblond and
- Jens Kastrup
Background: Many patients with chronic ischemic heart disease (CIHD) suffer from angina pectoris despite revascularization and maximum medical therapy.
We aimed to evaluate the effect of intra-myocardial injections of autologous vascular endothelial growth factor (VEGF-A165) stimulated adipose-derived stromal cells (ASCs) in patients with CIHD and refractory angina.
Methods: MyStromalCell trial is a randomised double-blind placebo-controlled study including sixty patients with CIHD, Canadian Cardiovascular Society (CCS)/New York Heart Association (NYHA) class II-III, left ventricular ejection fraction>40% and at least one significant coronary artery stenosis. Patients were treated with intra-myocardial injections of ASC or placebo in a 2:1 ratio. ASCs from abdominal adipose tissue were culture expanded and stimulated with VEGF-A165. Primary outcome was improvement in bicycle exercise tolerance 6 months after treatment.
Results: Fifty-six patients completed 6 months follow-up (37 ASC and 19 placebo). Patients receiving ASCs improved significantly from baseline to 6 months follow-up for bicycle exercise test in time duration (383 ± 16s to 407 ± 19s; P=0.034), work capacity measured in watt (81 ± 3 to 85 ± 4; P=0.048) and metabolic equivalents (4.2 ± 0.1 to 4.4 ± 0.2; P=0.048) while these remained unchanged in the placebo group (P=0.869, P=0.41 and P=0.757, respectively). There were no differences between groups.
There were significant reductions in CCS class, NYHA class, weekly angina attacks and increased quality-of-life score in both groups. There were no significant differences between the groups, however a trend towards higher improvements in the ASC group was observed.
Conclusions: Intra-myocardial delivered VEGF-A165 stimulated ASCs may improve work capacity and symptoms in patients with CIHD and refractory angina.
Moderated Poster Contributions
Acute and Stable Ischemic Heart Disease Moderated Poster Theater, Poster Hall, Hall C
Friday, March 17, 2017, 4:00 p.m.-4:10 p.m.
Session Title: Fixing the Heart One Cell at a Time: The Ongoing Promise of Stem Cells
Abstract Category: 2. Acute and Stable Ischemic Heart Disease: Clinical
Presentation Number: 1178M-05
- 2017 American College of Cardiology Foundation